Related Experiment Video
Updated: May 15, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5
Jonathan S Wall1, Tina Richey, Sally Macy
1Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA. jwall@utmck.edu
Summary
This study shows that 125I-labeled peptide p5 accurately quantifies amyloid deposits in mice. This molecular imaging probe demonstrates a strong correlation between uptake and amyloid load, suggesting its potential for human disease imaging.
Area of Science:
- Biomedical imaging
- Molecular diagnostics
- Amyloidosis research
Background:
- Non-invasive molecular imaging is crucial for assessing amyloid deposits.
- Accurate quantitation requires a linear correlation between probe uptake and amyloid load.
- AA amyloidosis is a significant disease requiring reliable diagnostic tools.
Purpose of the Study:
- To evaluate 125I-labeled peptide p5 as a quantitative imaging agent for peripheral amyloid deposits.
- To establish a correlation between 125I-p5 uptake and amyloid burden in a mouse model.
- To assess the potential of peptide p5 for clinical amyloid imaging.
Main Methods:
- Utilized a transgenic H-2/IL-6 mouse model of AA amyloidosis.
- Administered 125I-labeled peptide p5 and analyzed tissues via Congo red staining, biodistribution, and micro-autoradiography (ARG).
- Quantified amyloid load and probe deposition in liver and spleen.
Main Results:
- Micro-ARG confirmed 125I-p5 deposition specifically at amyloid sites.
- Biodistribution studies showed a significant positive correlation (r > 0.7, p < 10(-6)) between 125I-p5 uptake and amyloid load in liver and spleen.
- Demonstrated that 125I-p5 deposition quantitatively reflects AA amyloid levels in these organs.
Conclusions:
- 125I-labeled peptide p5 serves as a quantitative measure of AA amyloid in the spleen and liver of this mouse model.
- Peptide p5 shows promise as a quantitative molecular imaging agent for human amyloid diseases.
- This approach could aid in diagnosis, prognostication, and therapy monitoring for amyloidosis.
